Copyright © Inderes 2011 - present. All rights reserved.
  • Uusimmat
  • Pörssi
    • Aamukatsaus
    • Osakevertailu
    • Pörssikalenteri
    • Osinkokalenteri
    • Analyysi
    • Artikkelit
    • Sisäpiirin kaupat
  • inderesTV
  • Mallisalkku
  • Foorumi
  • Premium
  • Femme
  • Opi
    • Sijoituskoulu
    • Q&A
    • Analyysikoulu
  • Meistä
    • Seurantayhtiöt
    • Tiimi
Kolmannen osapuolen analyysi

Generic: A rare miss in Q2 - ABG

Generic Sweden

Tämä on kolmannen osapuolen analyysi, eikä välttämättä vastaa Inderesin näkemystä tai arvoja

Lataa raportti (PDF)
Slower sales growth than we have become used to

We lower long-term EBIT by 5%

Lifted COVID-19 restrictions boost new sales

Q2: Net sales +6% y-o-y, EBIT margin of 17.2% (20.4%)
Generic reported Q2 net sales of SEK 31.3m (29.6), representing a slower growth rate than we have become accustomed to. A combination of tough comparables alongside a slightly lower growth rate from existing customer explains the lower growth rate. Net sales were 4% behind ABGSCe, a rare miss from Generic. EBIT was SEK 5.4m (6.0m) for a margin of 17.2% (20.4%). We expected a lower EBIT margin based on a need to strengthen the organisation with additional employees, but still forecasted 17.7%. Looking forward, the company thinks it will benefit from lifted COVID-19 restrictions given that trade shows, events and physical meetings are important for its ability to sign new customers. We think this is a viable explanation and at least partly explains the relative paucity of new deals during the pandemic.

Still well-positioned, but negative revisions to forecast
We are not that worried about the Q2 miss, as we think digital communication will be increasingly important for a lot of companies in the years to come. In Q2’21, Generic onboarded the Swedish Social Insurance Agency as a new customer, driving additional sales. The company also benefitted from additional messaging volumes during 2021 which is why it may take a quarter or two to reach back to +10% sales growth, but we think the possibility is still there in the medium-term. However, we do lower our sales estimates by 2-4% for ’22-‘24e, respectively, and EBIT for the same period by 4-5%.

Trading below its own historical valuation
The Q2 shortfall did not go unnoticed by the market with the stock down 18% on the day of the report and -32% over the last month. We note that the valuation multiples have decreased significantly and that Generic is now trading more than 50% below its own two-year historical multiples for EV/EBIT NTM.
Läs mer på ABG Sundal Collier
Sosiaalinen media
  • Inderes Foorumi
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Yhteystiedot
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • Meistä
  • Tiimi
  • Avoimet työpaikat
  • Inderes sijoituskohteena
  • Palvelut pörssiyhtiöille
Sivusto
  • UKK
  • Käyttöehdot
  • Tietosuojaseloste
  • Vastuuvapauslauseke
Inderesin vastuuvapauslauseke löytyy täältä. Kunkin Inderesin aktiivisessa seurannassa olevan osakkeen tarkemmat tiedot löytyvät kunkin osakkeen omilta yhtiösivuilta Inderes-sivustolla. © Inderes Oyj. Kaikki oikeudet pidätetään.